With two new ex­pen­sive gene ther­a­py ap­provals, out­comes-based pric­ing deals grab the spot­light again

Two re­cent ap­provals for two ex­pen­sive gene ther­a­pies for blood dis­or­ders — Bio­Marin’s $1.5 mil­lion Roc­ta­vian in the EU for he­mo­phil­ia A and blue­bird bio’s …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER